Research Highlights

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for November 2023.

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for October 2023.

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for September 2023.

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for June 2023.

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for May 2023.

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for April 2023.

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for March 2023.

The 2017 McDonald criteria showed higher sensitivity, lower specificity, and similar accuracy in predicting clinically definite multiple sclerosis compared to 2010 McDonald criteria, while shortening time to its diagnosis.

Insidious disability accrual starts already in the earliest phases of multiple sclerosis and becomes dominant over the disease course, suggesting an ongoing process of inflammation and/or degeneration secondary to disease burden.

Epstein-Barr virus infection is the strongest known risk factor for the development of multiple sclerosis, and it precedes preclinical manifestation of the disease suggesting a possible causal role

In multiple sclerosis, an impairment of the glymphatic system may contribute to pathology accrual in the central nervous system and disability progression.

Baseline characteristics of Aβ-positive individuals can help identify those who will remain tau-negative for at least 5 years.

Greater diffusion restriction in the white matter of amyloid-beta-positive cognitively unimpaired individuals supports the role of inflammation in early preclinical AD.

New Neurology Update from Stroke Scientific Panel

The revised Boston criteria allow for a more accurate diagnosis of cerebral amyloid angiopathy